Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management

The purpose of this study is to determine if taking insulin glargine twice a day instead of once a day will better manage pregestational diabetes in pregnant patients. Participants in this study will be randomly assigned to one of two groups: a group that takes insulin glargine once a day, and a group that takes it twice. Continuous glucose monitoring will be used to track blood sugar levels. The main question the study aims to answer is: Will using insulin glargine twice a day instead of once lead to a better glucose time in range?

NCT Number	NCT07224893
Lead Sponsor	Eastern Virginia Medical School
Conditions	Pregestational Diabetes, Pregnancy
Enrollment	200 participants
Start Date	2026-05-18
Primary Completion	2027-12-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-15